-
Pfizer plans to submit new data to the Food and Drug Administration this week, bringing families with young children one step closer to a long-awaited vaccine.
-
Doctors have begun reporting cases of patients who see their symptoms return several days after treatment.
-
A corporate CEO’s call for a fourth mRNA shot struck those closely watching the pandemic as self-serving. It creates public pressure for a fourth dose of vaccine before government experts have time to assess the evidence and settle on the best course forward.
-
Drug manufacturers invested in Russia’s pharmaceutical industry contend international humanitarian law requires they continue manufacturing and selling their products there, even while condemning the Ukraine invasion.
-
The consensus has been that Pfizer and Moderna are most protective. But a study looking at 5 vaccines — including Russia's Sputnik V and two Chinese types — offers an unexpected finding.
-
"We believe additional information regarding the ongoing evaluation of a third dose should be considered as part of our decision-making for potential authorization," FDA officials said in a statement.
-
The Pfizer vax could soon be available for kids under 5. Doctors say families should start preparingPediatric hospitalizations remain high in Florida. Doctors say extending vaccine eligibility to little ones could help protect them in the future.
-
The authorization comes in the midst of an explosion of COVID-19 cases nationwide driven by the omicron variant — a surge that has brought a spike in pediatric hospitalizations.
-
The Pfizer treatment could help keep people infected with the coronavirus from getting so sick that they need to be hospitalized.
-
The Moderna vaccine's ability to shield against infection drops sharply when tested on the omicron variant. But getting a booster pumps the protection back up again, new research suggests.